Compare WSC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSC | LQDA |
|---|---|---|
| Founded | 1944 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 2015 | 2020 |
| Metric | WSC | LQDA |
|---|---|---|
| Price | $19.08 | $40.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $24.14 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 1.8M | 952.0K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,281,446,000.00 | $158,320,000.00 |
| Revenue This Year | N/A | $278.87 |
| Revenue Next Year | $3.54 | $57.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $14.91 | $11.85 |
| 52 Week High | $31.88 | $46.67 |
| Indicator | WSC | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 61.28 |
| Support Level | $18.49 | $31.75 |
| Resistance Level | $19.63 | $46.67 |
| Average True Range (ATR) | 0.81 | 1.84 |
| MACD | 0.28 | 0.29 |
| Stochastic Oscillator | 78.78 | 89.80 |
WillScot Holdings Corp designs, delivers, and services on-site, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company include modular office complexes, mobile offices, classrooms, blast-resistant modules, clearspan structures, sanitation solutions, portable storage containers, and climate-controlled containers and trailers.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.